BR100 Increased By (0.85%)
BR30 Increased By (1.2%)
KSE100 Increased By (0.41%)
KSE30 Increased By (0.56%)
AGHA 6.08 Decreased By ▼ -0.26 (-4.1%)
BECO 3.96 Decreased By ▼ -0.03 (-0.75%)
BML 58.25 Decreased By ▼ -0.46 (-0.78%)
BOP 27.22 Decreased By ▼ -0.08 (-0.29%)
CNERGY 12.30 Decreased By ▼ -0.10 (-0.81%)
CSIL 5.00 Decreased By ▼ -0.09 (-1.77%)
FCCL 51.61 Increased By ▲ 1.96 (3.95%)
FFL 13.08 Decreased By ▼ -0.28 (-2.1%)
FNEL 1.06 Decreased By ▼ -0.01 (-0.93%)
KEL 5.65 Increased By ▲ 0.10 (1.8%)
KOSM 5.21 Increased By ▲ 0.11 (2.16%)
LOTCHEM 22.51 Decreased By ▼ -0.53 (-2.3%)
MLCF 88.83 Increased By ▲ 2.20 (2.54%)
NBP 151.08 Increased By ▲ 1.39 (0.93%)
NCPL 48.54 Increased By ▲ 0.37 (0.77%)
NPL 53.09 Decreased By ▼ -0.47 (-0.88%)
OGDC 300.92 Increased By ▲ 2.80 (0.94%)
PACE 9.30 Increased By ▲ 0.07 (0.76%)
PAEL 32.40 Increased By ▲ 0.35 (1.09%)
PIBTL 12.89 Increased By ▲ 0.34 (2.71%)
PPL 212.36 Increased By ▲ 2.19 (1.04%)
PRL 95.71 Increased By ▲ 1.19 (1.26%)
PTC 44.30 Decreased By ▼ -0.99 (-2.19%)
SSGC 22.53 Increased By ▲ 0.01 (0.04%)
TBL 8.84 Increased By ▲ 0.17 (1.96%)
TELE 6.55 Decreased By ▼ -0.11 (-1.65%)
TPL 21.41 Decreased By ▼ -0.20 (-0.93%)
TPLP 11.51 No Change ▼ 0.00 (0%)
TREET 22.29 Increased By ▲ 0.12 (0.54%)
TRG 53.68 Increased By ▲ 1.14 (2.17%)
World

Sweden halts use of Moderna vaccine for young adults

Published Updated
By

STOCKHOLM: Sweden's Public Health Agency on Wednesday recommended a temporary halt to the use of the Moderna Covid-19 vaccine among young adults, citing concerns over rare side effects to the heart.

It said the pause should initially be in force until December 1, explaining that it had received evidence of an increased risk of side effects such as inflammation of the heart muscle (myocarditis) and inflammation of the pericardium (pericarditis).

"The Public Health Agency has decided to pause the use of Moderna's vaccine Spikevax, for everyone born 1991 and after, for cautionary reasons," the agency said in a statement, adding that those groups should instead receive the Pfizer/BioNTech vaccine.

According to the agency, the risk seemed especially tied to the second dose of the Moderna vaccine and was more prevalent among young men and boys, and in the weeks just following the second jab.

The symptoms usually pass by themselves, but should be evaluated by a doctor, it added.

Moderna says its Covid-19 shot 93% effective six months after second dose

"Those who are vaccinated recently, with their first or second dose of Moderna's vaccine, don't need to feel worried because the risk is very minor, but it is good to know which symptoms you should be on the lookout for," state epidemiologist Anders Tegnell said in a statement.

Some 81,000 people in the age group have already received a first jab in Sweden, but they will not be offered a second, the agency said, adding that "discussions were ongoing about the best solution for this group."

The European Medicines Agency (EMA) authorised the emergency use of Moderna's Covid-19 vaccine for teens in July.

Comments

Comments are closed for this article.